263 related articles for article (PubMed ID: 33914025)
1. Modeling Strategies to Optimize Cancer Screening in USPSTF Guideline-Noncompliant Women.
Taksler GB; Peterse EFP; Willems I; Ten Haaf K; Jansen EEL; de Kok IMCM; van Ravesteyn NT; de Koning HJ; Lansdorp-Vogelaar I
JAMA Oncol; 2021 Jun; 7(6):885-894. PubMed ID: 33914025
[TBL] [Abstract][Full Text] [Related]
2. The aggregate value of cancer screenings in the United States: full potential value and value considering adherence.
Philipson TJ; Durie T; Cong Z; Fendrick AM
BMC Health Serv Res; 2023 Aug; 23(1):829. PubMed ID: 37550686
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the Benefits and Harms of Lung Cancer Screening With Low-Dose Computed Tomography: Modeling Study for the US Preventive Services Task Force.
Meza R; Jeon J; Toumazis I; Ten Haaf K; Cao P; Bastani M; Han SS; Blom EF; Jonas DE; Feuer EJ; Plevritis SK; de Koning HJ; Kong CY
JAMA; 2021 Mar; 325(10):988-997. PubMed ID: 33687469
[TBL] [Abstract][Full Text] [Related]
4. Estimated US Cancer Deaths Prevented With Increased Use of Lung, Colorectal, Breast, and Cervical Cancer Screening.
Knudsen AB; Trentham-Dietz A; Kim JJ; Mandelblatt JS; Meza R; Zauber AG; Castle PE; Feuer EJ
JAMA Netw Open; 2023 Nov; 6(11):e2344698. PubMed ID: 37991759
[TBL] [Abstract][Full Text] [Related]
5. Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants: A Comparative Modeling Analysis.
Lowry KP; Geuzinge HA; Stout NK; Alagoz O; Hampton J; Kerlikowske K; de Koning HJ; Miglioretti DL; van Ravesteyn NT; Schechter C; Sprague BL; Tosteson ANA; Trentham-Dietz A; Weaver D; Yaffe MJ; Yeh JM; Couch FJ; Hu C; Kraft P; Polley EC; Mandelblatt JS; Kurian AW; Robson ME;
JAMA Oncol; 2022 Apr; 8(4):587-596. PubMed ID: 35175286
[TBL] [Abstract][Full Text] [Related]
6. Cancer Screening Disparities Before and After the COVID-19 Pandemic.
Lofters AK; Wu F; Frymire E; Kiran T; Vahabi M; Green ME; Glazier RH
JAMA Netw Open; 2023 Nov; 6(11):e2343796. PubMed ID: 37983033
[TBL] [Abstract][Full Text] [Related]
7. Provider Attitudes and Screening Practices Following Changes in Breast and Cervical Cancer Screening Guidelines.
Haas JS; Sprague BL; Klabunde CN; Tosteson AN; Chen JS; Bitton A; Beaber EF; Onega T; Kim JJ; MacLean CD; Harris K; Yamartino P; Howe K; Pearson L; Feldman S; Brawarsky P; Schapira MM;
J Gen Intern Med; 2016 Jan; 31(1):52-9. PubMed ID: 26129780
[TBL] [Abstract][Full Text] [Related]
8. Lung Cancer Screening in Brazil Comparing the 2013 and 2021 USPSTF Guidelines.
Emmerick ICM; Campos MR; Castanheira D; Muzy J; Marques A; Arueira Chaves L; Sobreira da Silva MJ
JAMA Netw Open; 2023 Dec; 6(12):e2346994. PubMed ID: 38079172
[TBL] [Abstract][Full Text] [Related]
9. Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study.
Rutter CM; Kim JJ; Meester RGS; Sprague BL; Burger EA; Zauber AG; Ergun MA; Campos NG; Doubeni CA; Trentham-Dietz A; Sy S; Alagoz O; Stout N; Lansdorp-Vogelaar I; Corley DA; Tosteson ANA
Cancer Epidemiol Biomarkers Prev; 2018 Feb; 27(2):158-164. PubMed ID: 29150480
[No Abstract] [Full Text] [Related]
10. Screening Beyond the Evidence: Patterns of Age and Comorbidity for Breast, Cervical, and Colorectal Cancer Screening.
Onega T; Garcia M; Beaber EF; Haas JS; Breslau ES; Tosteson ANA; Halm E; Chao CR; Barlow WE
J Gen Intern Med; 2024 Jun; 39(8):1324-1331. PubMed ID: 38097863
[TBL] [Abstract][Full Text] [Related]
11. Trends in Breast Cancer Screening: Impact of U.S. Preventive Services Task Force Recommendations.
Dehkordy SF; Hall KS; Roach AL; Rothman ED; Dalton VK; Carlos RC
Am J Prev Med; 2015 Sep; 49(3):419-22. PubMed ID: 25841980
[TBL] [Abstract][Full Text] [Related]
12. A population-based survey of self-reported delays in breast, cervical, colorectal and lung cancer screening.
Gunn CM; Berrian K; Weiss JE; Tosteson AAN; Hasson RM; Di Florio-Alexander R; Peacock JL; Rees JR
Prev Med; 2023 Oct; 175():107649. PubMed ID: 37517458
[TBL] [Abstract][Full Text] [Related]
13. Breast and cervical cancer screenings across gender identity: results from the Behavioral Risk Factor Surveillance System before and during the COVID-19 pandemic.
Berzansky I; Reynolds CA; Charlton BM
Cancer Causes Control; 2024 May; 35(5):865-872. PubMed ID: 38280155
[TBL] [Abstract][Full Text] [Related]
14. Impact of the 2009 US Preventive Services Task Force guidelines on screening mammography rates on women in their 40s.
Wang AT; Fan J; Van Houten HK; Tilburt JC; Stout NK; Montori VM; Shah ND
PLoS One; 2014; 9(3):e91399. PubMed ID: 24618830
[TBL] [Abstract][Full Text] [Related]
15. [Analysis of predictive factors for non-adherence to organized screening for colorectal and breast cancers in the pre-pandemic period (2018-2019) in Lombardy Region (Northern Italy)].
Russo AG; Murtas R; Ballotari P; Cavalieri d'Oro L; Gambino ML; Fanetti AC; Maifredi G; Manzoni F; Sampietro G; Leoni O; Celata C; Cereda D; Deandrea S;
Epidemiol Prev; 2024; 48(2):118-129. PubMed ID: 38770729
[TBL] [Abstract][Full Text] [Related]
16. Breast, cervical, and colorectal cancer screening test use in the US territories of Guam, Puerto Rico, and the US Virgin Islands.
Gopalani SV; Soman A; Shapiro JA; Miller JW; Ortiz-Ortiz KJ; Castañeda-Avila MA; Buenconsejo-Lum LE; Fredericks LE; Tortolero-Luna G; Saraiya M
Cancer Epidemiol; 2023 Jun; 84():102371. PubMed ID: 37105018
[TBL] [Abstract][Full Text] [Related]
17. Le disuguaglianze di accesso ai programmi di screening dei tumori della mammella, del colon retto e della cervice uterina sono aumentate durante il periodo pandemico. Risultati di un health equity audit condotto dall'Agenzia di Tutela della Salute d.
Girardi D; Vecchio R; Tanious M; Cacitti S; Ancarani C; Dalle Carbonare S; Perotti P; Bonafede C; Cavallo R; Gentile L; Parrini A; Lucente EM; Carlesso A; Cadum E; Cecconami L; Odone A; Deandrea S
Epidemiol Prev; 2024; 48(2):130-139. PubMed ID: 38770730
[TBL] [Abstract][Full Text] [Related]
18. National Breast, Cervical, and Colorectal Cancer Screening Use in Federally Qualified Health Centers.
Amboree TL; Montealegre JR; Parker SL; Garg A; Damgacioglu H; Schmeler KM; Chiao EY; Hill EG; Sonawane K; Deshmukh AA; Adsul P
JAMA Intern Med; 2024 Jun; 184(6):671-679. PubMed ID: 38683574
[TBL] [Abstract][Full Text] [Related]
19. 5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study.
Luo YH; Luo L; Wampfler JA; Wang Y; Liu D; Chen YM; Adjei AA; Midthun DE; Yang P
Lancet Oncol; 2019 Aug; 20(8):1098-1108. PubMed ID: 31255490
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
